Last reviewed · How we verify

antioxidants

University of Washington · FDA-approved active Small molecule Quality 0/100

Antioxidants, developed by the University of Washington, are currently marketed but lack a specified primary indication or revenue data. The key composition patent is set to expire in 2028, which may provide a temporary barrier to generic competition. However, the absence of detailed clinical trial results and identified competitors poses a significant risk to assessing the drug's market sustainability and competitive landscape.

At a glance

Generic nameantioxidants
Also known asBio-selenium, Pharma Nord (DK), Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC), alpha-Lipoic acid (ALA), DEKAS Plus
SponsorUniversity of Washington
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: